Statistical Methods for Handling Intentional Inaccurate Responders

In self-report data, participants who provide incorrect responses are known as intentional inaccurate responders. This dissertation provides statistical analyses for address intentional inaccurate responses in the data. Previous work with adolescent self-report, labeled survey participants who intentionally provide inaccurate answers as mischievous responders. This phenomenon also occurs in clinical research. For example, pregnant women who smoke may report that they are nonsmokers. Our advantage is that we do not solely have self-report answers and can verify responses with lab values. Currently, there is no clear method for handling these intentional inaccurate respondents when it comes to making statistical inferences. We propose a using an EM algorithm to account for the intentional behavior while maintaining all responses in the data. The performance of this model is evaluated using simulated data and real data. The strengths and weaknesses of the EM algorithm approach will be demonstrated

Effects of the Dual Orexin Receptor Antagonist DORA-22 on Sleep in 5XFAD Mice

Introduction: Sleep disruption is a characteristic of Alzheimer\u27s disease (AD) that may exacerbate disease progression. This study tested whether a dual orexin receptor antagonist (DORA) would enhance sleep and attenuate neuropathology, neuroinflammation, and cognitive deficits in an AD-relevant mouse model, 5XFAD. Methods: Wild-type (C57Bl6/SJL) and 5XFAD mice received chronic treatment with vehicle or DORA-22. Piezoelectric recordings monitored sleep and spatial memory was assessed via spontaneous Y-maze alternations. Aβ plaques, Aβ levels, and neuroinflammatory markers were measured by immunohistochemistry, enzyme-linked immunosorbent assay, and real-time polymerase chain reaction, respectively. Results: In 5XFAD mice, DORA-22 significantly increased light-phase sleep without reducing Aβ levels, plaque density, or neuroinflammation. Effects of DORA-22 on cognitive deficits could not be determined because the 5XFAD mice did not exhibit deficits. Discussion: These findings suggest that DORAs may improve sleep in AD patients. Further investigations should optimize the dose and duration of DORA-22 treatment and explore additional AD-relevant animal models and cognitive tests